Company / Shareholders' Equity
KalVista Pharmaceuticals, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$95.4M
FY2025
5-year range
$95.4M / $257.2M
FY2021-FY2025
Trend
-53.8%
vs FY2024
Sector context
#173 of 213
Health Care
What the data says
KalVista Pharmaceuticals, Inc.'s shareholders' equity of $95M is lower than 81% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 10 years, ranging from -$37M in FY2019 to $257M in FY2021.
Based on SEC 10-K filings.
$95M in FY2025 with a 5-year CAGR of +2.6%.
Declined from $161M to $95M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -19.8%
- 5-Year CAGR
- +2.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 213This company $95.4M Sector average $2.5B
▼
-96.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.6%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 53.8% year-over-year.
- Ranks #173 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $95.4M | -53.8% |
| FY2024 | $206.6M | +28.3% |
| FY2023 | $161.0M | -13.0% |
| FY2022 | $185.1M | -28.0% |
| FY2021 | $257.2M | +207.1% |
| FY2020 | $83.8M | +325.7% |
| FY2019 | -$37.1M | -57.6% |
| FY2018 | -$23.6M | -175.2% |
| FY2017 | $31.3M | +184.4% |
| FY2016 | -$37.1M | -57.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026